Analyst Matthew Galinko of Maxim Group maintained a Buy rating on Semler Scientific, retaining the price target of $95.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Galinko has given his Buy rating due to a combination of factors that highlight Semler Scientific’s strategic initiatives and financial outlook. The company has shown a strong commitment to accumulating Bitcoin, with a target to hold 10,000 BTC by the end of 2025 and significantly more in the following years. This accumulation strategy is supported by the company’s ability to raise substantial funds through share issuance, indicating a robust financial strategy.
Additionally, Semler Scientific is expanding its medical technology offerings, particularly with the formation of CardioVanta, a subsidiary focused on cardiovascular market opportunities. The anticipated approval of new diagnostic devices could broaden the company’s market reach and enhance revenue potential. Galinko’s valuation incorporates both the projected growth in Bitcoin holdings and the promising developments in the medical device sector, leading to a price target of $95 per share.
Galinko covers the Technology sector, focusing on stocks such as Intchains Group Ltd. ADR, SEALSQ Corp, and Ondas Holdings. According to TipRanks, Galinko has an average return of 5.8% and a 38.37% success rate on recommended stocks.
In another report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $60.00 price target.